[{"id":"c94e9288-548e-477e-9ce2-ce8edd57543b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05367778","created_at":"2022-05-10T20:53:42.002Z","updated_at":"2024-07-02T16:35:46.082Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05367778","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10370"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 06/03/2022","start_date":" 06/03/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-06-09"}]